Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4127655 | 0.99 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2HTT | |
| SCHEMBL4116091 | 0.88 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2HTT | |
| SCHEMBL13696794 | 0.85 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL13696779 | 0.84 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL5887986 | 0.84 | HPGD (0.54) | SLC6A2SLC6A4SLC6A3KCNH2GAA | |
| SCHEMBL5888222 | 0.84 | HPGD (0.54) | SLC6A2SLC6A4SLC6A3KCNH2GAA | |
| SCHEMBL4114669 | 0.83 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3KCNH2HTT | |
| SCHEMBL5888140 | 0.82 | HPGD (0.52) | SLC6A2SLC6A4SLC6A3KCNH2GAA | |
| SCHEMBL5888070 | 0.82 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL5887953 | 0.82 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239928-A1 | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239928-A1 | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | AOC3, AOC2, TPH2 | SLC6A2 5/4885SLC6A4 36/4885SLC6A3 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.